FDA Adverse Event Injury Summary report: N

PROGAV SYSTEM W/SA 20 A.SPRUNG RESERVOIR

MDR report key: 18055769 · Received November 2, 2023

Report

Report Number
3004721439-2023-00323
Event Type
Injury
Date Received
November 2, 2023
Date of Event
September 10, 2023
Report Date
November 2, 2023
Manufacturer
CHRISTOPH MIETHKE GMBH & CO KG
Product Code
JXG
UDI-DI
04041906132248
PMA / PMN Number
K103003
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

INVESTIGATION: VISUAL INSPECTION: DURING THE INVESTIGATION, DEPOSITS ON THE DEVICE WAS DETERMINED. PERMEABILITY TEST: A PERMEABILITY TEST HAS SHOWN THAT ALL COMPONENTS ARE PERMEABLE. COMPUTER CONTROLLED TEST: TO INVESTIGATE THE CLAIM OF OVER- DRAINAGE, THE OPENING PRESSURE IS MEASURED USING A MIETHKE COMPUTER CONTROLLED TESTING APPARATUS WHICH SIMULATES A CEREBROSPINAL FLUID FLOW. THE VALVES ARE TESTED IN BOTH THE HORIZONTAL AS WELL AS THE VERTICAL POSITIONS. THE RESULTS SHOW THAT THE VALVES OPERATE WITHIN THE ACCEPTED TOLERANCE IN BOTH POSITIONS. ADJUSTMENT TEST: THE PROGAV WAS TESTED AND IS NOT ADJUSTABLE. BRAKING FORCE AND BRAKE FUNCTION TEST: THE BRAKE FUNCTIONALITY TEST HAS SHOWN THAT THE BRAKE FUNCTION IS OPERATIONAL, BUT THE BRAKING FORCE CANNOT BE MEASURED DUE TO THE NON-ADJUSTABILITY OF THE VALVE. INTERNAL INSPECTION : AFTER DISMANTLING OF THE VALVES, DEPOSITS WERE FOUND IN BOTH VALVES. RESULTS : IN ADVANCE, WE WOULD LIKE TO POINT OUT THAT THE PRODUCT SENT IN WAS NOT SUBMERGED IN LIQUID AT THE TIME OF DELIVERY. THE TESTING OF DRY VALVES IS ONLY OF LIMITED VALUE. THE PRODUCT PROPERTIES CAN BE INFLUENCED BY DRY RESIDUES OF CEREBROSPINAL FLUID OR BLOOD. DESPITE THIS, WE HAVE EXAMINED THE VALVE. BASED ON OUR INVESTIGATION RESULTS, WE CAN DETERMINE A NON- ADJUSTABILITY ON THE PROGAV VALVE. THE DETERMINED DEPOSITS CAN BE NAMED AS THE CAUSE FOR THE ADJUSTMENT DIFFICULTIES. THE DETERMINED DEPOSITS IN THE SHUNT ASSISTANT HAD NO EFFECT TO THE TECHNICAL PROPERTIES AT THE TIME OF THE INVESTIGATION. PROTEINS IN THE CEREBROSPINAL FLUID CAN INFLUENCE THE FUNCTION TEMPORARILY AND ARE KNOWN SIDE EFFECTS IN HYDROCEPHALUS THERAPY. WE CAN EXCLUDE A DEFECT AT THE TIME OF RELEASE. THE SHUNT SYSTEM MET ALL SPECIFICATIONS OF THE FINAL INSPECTION WHEN RELEASED FROM CHRISTOPH MIETHKE GMBH & CO. KG. NO FURTHER REGULATORY ACTIONS ARE REQUIRED FROM OUR POINT OF VIEW.

Description of Event or Problem · 0

IT WAS REPORTED THAT A PROGAVSHUNTSYSTEM (#FV427T) WAS IMPLANTED DURING A PROCEDURE PERFORMED ON (B)(6) 2014. ACCORDING TO THE COMPLAINANT, THE SHUNT SYSTEM CAUSED AN OVERDRAINAGE AND HAD ADJUSTMENT DIFFICULTIES. THE PATIENT UNDERWENT A REVISION PROCEDURE. THE COMPLAINANT DEVICE WAS RETURNED TO THE MANUFACTURER FOR EVALUATION. NO PATIENT COMPLICATIONS WERE REPORTED AS A RESULT OF THE REVISION PROCEDURE. AGE: 12 YEARS, 8 MONTHS. HEIGHT: 163 CENTIMETERS. WEIGHT: 69 KILOGRAMS. GENDER: FEMALE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1928008 PROGAV SYSTEM W/SA 20 A.SPRUNG RESERVOIR HYDROCEPHALUS MANAGEMENT JXG CHRISTOPH MIETHKE GMBH & CO KG FV427T 20022086 04041906132248

Patients

Seq Age Sex Outcome Treatment
1 12 YR Female Required Intervention